PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 6 :
C12N 15/12, 15/63, 15/70, 15/79, C07K 14/705

A1

(11) International Publication Number: WO 97/08316

(43) International Publication Date: 6 March 1997 (06.03.97)

(21) International Application Number: PCT/US96/13805

(22) International Filing Date: 27 August 1996 (27.08.96)

(30) Priority Data:
60/003,020 31 August 1995 (31.08.95) US

(71) Applicant *(for all designated States except US)*: MERCK & CO., INC. [US/US]; 126 East Lincoln Avenue, Rahway, NJ 07065 (US).

(72) Inventors; and
(75) Inventors/Applicants *(for US only)*: DUONG, Le, T. [US/US]; 126 East Lincoln Avenue, Rahway, NJ 07065 (US). NUTT, Elka, M. [US/US]; 126 East Lincoln Avenue, Rahway, NJ 07065 (US). RODAN, Gideon, A. [US/US]; 126 East Lincoln Avenue, Rahway, NJ 07065 (US).

(74) Common Representative: MERCK & CO., INC.; 126 East Lincoln Avenue, Rahway, NJ 07065 (US).

(81) Designated States: CA, JP, US, European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE).

Published
With international search report.

(54) Title: MOUSE INTEGRIN SUBUNITS

(57) Abstract

The full-length mouse $\beta 3$ integrin has been cloned and sequenced. A new form of $\beta 3$ integrin ($\beta 3$-trunc) also has been cloned and sequenced.

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AM	Armenia
AT	Austria
AU	Australia
BB	Barbados
BE	Belgium
BF	Burkina Faso
BG	Bulgaria
BJ	Benin
BR	Brazil
BY	Belarus
CA	Canada
CF	Central African Republic
CG	Congo
CH	Switzerland
CI	Côte d'Ivoire
CM	Cameroon
CN	China
CS	Czechoslovakia
CZ	Czech Republic
DE	Germany
DK	Denmark
EE	Estonia
ES	Spain
FI	Finland
FR	France
GA	Gabon
GB	United Kingdom
GE	Georgia
GN	Guinea
GR	Greece
HU	Hungary
IE	Ireland
IT	Italy
JP	Japan
KE	Kenya
KG	Kyrgystan
KP	Democratic People's Republic of Korea
KR	Republic of Korea
KZ	Kazakhstan
LI	Liechtenstein
LK	Sri Lanka
LR	Liberia
LT	Lithuania
LU	Luxembourg
LV	Latvia
MC	Monaco
MD	Republic of Moldova
MG	Madagascar
ML	Mali
MN	Mongolia
MR	Mauritania
MW	Malawi
MX	Mexico
NE	Niger
NL	Netherlands
NO	Norway
NZ	New Zealand
PL	Poland
PT	Portugal
RO	Romania
RU	Russian Federation
SD	Sudan
SE	Sweden
SG	Singapore
SI	Slovenia
SK	Slovakia
SN	Senegal
SZ	Swaziland
TD	Chad
TG	Togo
TJ	Tajikistan
TT	Trinidad and Tobago
UA	Ukraine
UG	Uganda
US	United States of America
UZ	Uzbekistan
VN	Viet Nam

BNSDOCID: <WO 9708316A1>

TITLE OF THE INVENTION
MOUSE INTEGRIN SUBUNITS

DESCRIPTION OF THE INVENTION:

This invention relates to a new mouse vitronectin receptor subunit β3 (β3-trunc), the full length mouse vitronectin receptor, their nucleic acids, and to assays using these receptors. Additionally this invention includes soluble integrins which lack transmembrane and cytoplasmic domains.

BACKGROUND OF THE INVENTION

Integrins are transmembrane glycoproteins that mediate cell-cell and cell-matrix interactions. They contain two subunits, α and β, which are joined in a non-covalent complex. There are numerous α and β subunits known. Alpha subunits show some homology with other alpha subunits and beta subunits tend to show homology with other beta subunits, however, the alpha subunits tend to be quite distinct from beta subunits.

Osteoclasts are the primary cells responsible for bone resorption. Osteoclasts migrate to the area of the bone to be absorbed, and then attach to the bone. Adhesion molecules, including integrins, are believed to be involved in the processes of migration and attachment.

Recent studies have shown that both mature osteoclasts and tissue culture generated osteoclast-like cells highly express the vitronectin integrin receptor $\alpha_v\beta_3$. The $\alpha_v\beta_3$ integrin receptor recognizes the tripeptide Arg-Gly-Asp (RGD), found in many bone matrix proteins, and thus is thought to be involved in the attachment processes. However, there is no direct evidence that $\alpha_v\beta_3$ mediates osteoclast attachment to bone *in vivo*.

Partial sequence of the mouse β3 cDNA was previously reported by Cieutat, *et al.*, 1993 *Biochem. Biophys. Res. Comm.* 193:771-778. Cieutat *et al.*, cloned β3 from mouse kidney RNA using

RT/PCR and human primers. This published sequence did not have the N-terminus and the last 4 amino acids at the C-terminus.

There are presently two types of screens for the $\alpha_v\beta_3$ ligands as an inhibitor for bone resorption: a binding assay based on human recombinant $\alpha_v\beta_3$ integrin and a functional assay based on rodent osteoclasts. To exclude the possibility of species-based potency differences in ligand interaction with the $\alpha_v\beta_3$ integrin, it would be desirable to develop an assay which uses the β3 integrin subunit from a mouse osteoclast.

DETAILED DESCRIPTION OF THE INVENTION

This invention relates to the full length mouse β3 integrin subunit (β3), nucleic acids encoding it, and to processes for cloning it. Another aspect of this invention is a novel form of the β3 integrin subunit, referred to as β3-trunc, which lacks the transmembrane and cytoplasmic domains, to nucleic acids encoding it, and to processes for producing it. Another aspect of this invention is the use of these integrins in assays to identify novel compounds which inhibit the bone absorption process.

Yet another aspect of this invention is a soluble ligand-binding integrin which, like other soluble receptors, suppresses the interaction of the full length integrins with their ligands. The main signal transduction pathway mediated by the a membrane bound integrin is transduced through the cytoplasmic domain of the β subunit. A soluble receptor, which has an intact binding domain but lacks the cytoplasmic domain, will suppress or compete with the normal signals mediated by the wild type receptor.

BRIEF DESCRIPTION OF THE FIGURES

Fig. 1. is the complete sequence of the mouse β3 integrin (2.3 kb) cloned from a osteoclast cDNA library. The "ATG" initiation codon begins at position 164 and both a "TAA" and a "TGA" stop codons are seen starting at position 2525.

Fig. 2 is the cDNA of the mouse β3-trunc. The "ATG" initiation codon begins at position 164.

Fig. 3 is the amino acid sequence of mouse β3-trunc. This sequence shows the corresponding amino acids, including untranslated regions. Asterisks denote stop codons. As shown in Figure 5, the open reading frame begins with the "Met" at position 55, and ends with the "Ala" at position 782.

Fig. 4 is the amino acid sequence of the full-length mouse β3. This sequence shows corresponding amino acids, including untranslated regions. Asterisks denote stop codons. As shown in Figure 5, the open reading frame begins with the "Met" at position 55, and ends with the "Thr" at position 841.

Fig. 5 is an amino acid sequence comparison between the mouse full-length β3 (top line) and the mouse β3-trunc (lower line).

Fig. 6 are gels showing the expression of mouse full-length β3 and β3-trunc in osteoclast-like cells in the mouse co-culture system.

Fig. 7 are gels demonstrating the regulation of both β3 and β3-trunc by 1,25-dihydroxy Vitamin D3.

Fig. 8 are gels showing the expression of β3 and β3-trunc in various tissues.

Fig. 9 are diagrams of the mouse β3 and β3-trunc genes and the proteins encoded.

As used in the specification and claims, the following definitions shall apply:

"Free from associated mouse nucleic acid" - physically separated from mouse nucleic acid (DNA or RNA) which either (i) mouse β3 nucleic acid or (ii) mouse β3-trunc nucleic acid.

"Free from associated mouse DNA"-- physically separated from mouse DNA which is not either (i) mouse DNA encoding β3 integrin or (ii) DNA encoding truncated β3 integrin.

"Substantially pure"-- a protein or nucleic acid is "substantially pure" when the amount of other protein or nucleic acid present in a sample is less than about 5% of the sample by weight.

Thus one aspect of this invention is nucleic acids which encode the full length mouse β3 integrin, said nucleic acid being free from associated mouse nucleic acid. Preferably the nucleic acid is a DNA. A preferred type of DNA is cDNA, and a particularly preferred cDNA is that shown in Figure 1.

Partial sequence of the mouse β3 cDNA was previously reported by Cieutat, *et al.*, 1993 *Biochem. Biophys. Res. Comm.* 193:771-778, which is hereby incorporated by reference. Cieutat *et al* cloned β3 from mouse kidney RNA using RT/PCR and human primers. This published sequence did not have the N-terminus and the last 4 amino acids at the C-terminus. One aspect of this invention comprises a complete sequence of the mouse β3 integrin (2.3 kb) cloned from a osteoclast cDNA library, free from associated mouse cDNA,or which is substantially pure. This is presented in Figure 1. The sequence of β3 was derived from the cDNA sequence of clone 9A (from 5'-end to base 2028) and the PCR sequence of a fragment encoding the last 363 bases at the 3'-end.

Another aspect of this invention is the complete, full-length β3 peptide, free from associated mouse peptides, or substantially pure which is shown in Figure 4. Substantially pure mouse full-length β3 is another aspect of this invention.

Mouse β3 shows 86% homology with the human β3 at the DNA level, 90% overall homology in the amino acid sequence, 90% and 100% homology in the ligand binding domains (residues 109 - 171 and residues 204 - 229, respectively), 97% homology in the transmembrane domain and 100% identity in the cytoplasmic tail. This high homology is consistent with the quantitative similarity in the binding of ligands to human and mouse αvβ3.

Another aspect of this invention are vectors which comprise the full length mouse β3 nucleic acids, preferably cDNA and to host cells transformed with these vectors. Preferred host cells are embryonic kidney cells. This invention also includes the method of making full length β3 by transforming a host cell with a vector

comprising full length mouse β3 DNA and harvesting the β3 so produced.

Characterization of the truncated mouse β3 cDNA (β3-trunc):

Another aspect of this invention is nucleic acids which encode a truncated mouse β3 (β3-trunc) peptide, free from associated mouse nucleic acids, or which are substantially pure. A preferred form of β3-trunc DNA is cDNA; a particularly preferred cDNA is that shown in Figure 2.

Another aspect of this invention is the β3-trunc peptide, free from associated mouse peptides, or substantially pure. This is shown in Figure 3 and Figure 9. Mouse β3-trunc, which includes 5'-untranslated region (163 bp), 5'-coding region of the extracellular domain of β3 (up to base 2028 or residue 676) and a diversed 3'-coding region. Interestingly, the diversed 3'-coding region includes an in-frame addition of 43 amino acids, followed by a long 3'-untranslated sequence (1.2 kb). From homology analysis, this diversed 3'-sequence shows no significant homology with any known gene. The protein encoded by the β3-trunc gene contains the entire ligand binding and cysteine-rich domains, but lacks the transmembrane and cytoplasmic domains.

The expression of β3-trunc and its regulation in the co-culture-derived osteoclasts was investigated. Northern analysis of the co-culture, with either a 5'-probe or a 3'-specific β3-trunc probe, reveals that the osteoblastic MB 1.8 cells do not express β3 or β3-trunc (see Figure 6). However, the expression of both forms is highly enriched in the partially purified preparation of osteoclasts from the co-culture. The 5'-probe hybridizes to a major mRNA product at 6.5 kb and several minor forms of 2-4 kb. The β3-trunc specific probe detects a major mRNA product at 3 kb and two minor mRNA products at 2 and 4 kb. Generation of osteoclasts in the co-culture system depends on the presence of 1,25-dihydroxy Vitamin D3 (1,25(OH)2D3). Both forms of β3 integrin were up-regulated by 1,25(OH)2D3 treatment of the co-culture system as shown in Figure 7.

Murine tissue distribution reveals different patterns of expression for β3 and β3-trunc. This is demonstrated in Figure 8. Full length β3 is expressed in spleen>lung>liver, with a very minor amount of β3 messages (6.5kb) detected in other tissues. In contrast, β3-trunc (2-4 kb) messages are expressed in heart>skeletal muscle>brain>lung.

Since β3-trunc lacks the transmembrane and cytoplasmic domains, it can be considered a soluble ligand binding integrin. This represents the first such soluble integrin. Thus another aspect of this invention is an integrin which lacks the transmembrane and cytoplasmic domains. Such an integrin is able to circulate throughout the organism. Its physiological role appears to be suppression of the signaling pathway mediated by the full length β3 integrins interaction with their ligands. Integrin-ligand signals are generally transmitted to the cytoplasm by a mechanism involving the cytoplasmic domain. However, when a ligand binds to β3-trunc, which lacks such a domain, the signal would not reach the cytoplasm. Therefore, the soluble ligands can act as negative regulators, tying up ligand without signaling the cell.

Assays

Another aspect of this invention are novel assays. The novel assays of this invention are to identify inhibitors of human $\alpha_v\beta_3$ receptors. Such inhibitors would be useful in a variety of disease conditions including diseases associated with bone resorption such as osteoporosis. Generally, potential inhibitors are first screened for their ability to bind to recombinant human $\alpha_v\beta_3$ receptors using an assay such as the one set forth in Example 2. Further *in vitro* testing of the potential inhibitor, however, generally occurs using mouse or other rodent cell systems. It is not uncommon for the same potential inhibitor to display different responses in the two systems, and until now the investigator would not be able to determine if the differences were due to the effect of the different species' receptors or to actual *in vitro* activity.

Thus, in one aspect of this invention, a potential inhibitor to osteoclast formation is placed into contact with either mouse full length

β3 or mouse β3-trunc, and its ability to bind is measured. The binding may be measured by any known means, such as by measuring the displacement of a compound known to bind to β3, such as echistatin. This information can be used to better assess the activity of the potential inhibitor in an *in vitro* assay.

By means of example only, if a potential inhibitory compound were found to bind well to human $\alpha_v\beta_3$ in the recombinant $\alpha_v\beta_3$ assay, but exhibited less inhibitory activity than expected in the mouse *in vitro* assay, one could determine whether the decrease in expected activity was due to the compound's inability to bind efficiently to the mouse integrin or whether the decreased activity was a true reflection of the compound's *in vitro* activity, by performing a mouse β3 or β3-trunc assay.

The following non-limiting Examples are presented to further illustrate the invention.

EXAMPLES

General techniques

First-Strand cDNA synthesis kit and QuickPrep mRNA Purification Kit were from Pharmacia. Lamda ZAP II cloning kits were from Stratagene. Mouse tissue mRNA blots were purchased from Clontech. Hybond-N filters were from Amersham. Restriction enzymes were from various sources: BioLabs, Promega and Stratagene. Tissue culture media were from Gibco. Fetal bovine serum was obtained from JRH Bioscience.

EXAMPLE 1

Strategy for isolating cDNA clones for the mouse β3 subunit

Generation of a mouse β3 cDNA probe (mβ3 probe): This probe was generated using the following degenerate oligonucleotide primers:

5'-primer:
CCA AGC TTG AC(A/C) T(G/C)T ACT A(C/T)C T(G/T)A TGG A

3'-primer:
CCC TCG AGA A(A/G)T (C/T)GT CGC A(C/T)T CGC A(A/G)T A

The primers were designed based on a sequence which is highly conserved among all integrin β subunits (Ramaswamy & Hemler, 1990, *EMBO J.* 9: 1561-1568, which is incorporated by reference). Using polymerase chain reaction, a cDNA fragment of the β3 subunit was cloned from a cDNA library prepared from mouse osteoclasts. The identity of this mβ3 probe was confirmed by sequence analysis to be homologous to the published human β3 sequence (Frachet *et al.*, 1990 *Mol. Biol. Rep.* 14:27-33, which is hereby incorporated by reference.).

Construction of a λZAP mouse osteoclast cDNA library (λZAP-OC): The cDNA library was constructed from 5 μg polyA(+) RNA prepared from osteoclasts, which were generated from a co-culture of osteoblastic MB 1.8 cells and mouse bone marrow cells in the presence of 1,25-dihydroxy Vitamin D3 (1,25(OH)2D3). Methods for generation and isolation of mouse osteoclasts from culture were performed as described by Tanaka, *et al.*, 1991 *J. Bone Min. Res.* 6: S148, which is hereby incorporated by reference. The construction of this library was carried out according the instructions provided by the manufacturer, Stratagene (Lambda ZAP II Cloning Kits - 236611). Random pd(N)6 primers were used for the first strand cDNA synthesis.

Screening for mouse β3 clones: Mouse β3 cDNA clones were isolated by screening the primary λZAP-OC library (0.5 x 10^6 pfu), using the mβ3 probe. Sixteen positive clones were isolated and rescued into pBluescipt phagemid according to the manufacturer's protocol (Stratagene). These clones were initially characterized by restriction digestion with EcoRI to estimate the size of cDNA inserts. Clone 9A

was found to be the largest (3.5 Kb) and was subsequently characterized by sequence analysis.

Cloning of 3'-cDNA fragment of mouse β3 by PCR: Clone 9A encodes for the entire sequence of mouse β3-trunc, which lacks only 121 amino acids (363 bp) from the expected C-terminus of β3-full, based on the published human β3 sequence. Therefore, the rest of the 3'-cDNA fragment was cloned by PCR. The following primers were used:

5'-primer (from BstEII site of clone 9A):
TAA GGA CAG CCT CAC CGT CCA GGT

3'-primer (based on the human sequence):
TCA TTA AGT CCT CGG TAC GTG ATA TTG GTG

Full length mouse β3 cDNA was then constructed by ligating at the BstEII site between the clone 9A-derived 5'-fragment and the PCR clone-derived 3'-fragment.

RNA isolation and Northern blot analysis: Total cellular RNA was isolated by guanidine isothiocyanate and phenol extraction (Chomczynski & Sacchi, 1987, *Anal. Biochem.* 162:156-159.). Ten μg of total RNA was separated using formaldehyde-agarose gel electrophoresis, followed by transfer onto nylon filters (Hybond-N; Amersham). Poly A(+) RNA was prepared using QuickPrep mRNA Purification Kit (Pharmacia). Mouse tissue blots were purchased from Clontech. Mouse β3 specific probe was generated from the 5'-fragment of clone 9A using the EcoRI and BstEII sites. This probe can recognize both β3 full length and β3-trunc. Mouse β3-trunc specific probe was generated from the 3'-fragment of clone 9A using the Not I and EcoRI sites. Hybridizations were performed in 40% formamide, 5x SSC, 0.1% SDS, 0.1% ficoll, 0.1% polyvinylpyrolidone, 0.1% BSA and 200 mg/ml sonicated salmon sperm DNA at 42°C, overnight, and washed two times

(30 min) at 55°C in 0.1x SSC and 0.1% SDS. The filters were dried and exposed to XAR-2 films (Eastman Kodak, Rochester, NY).

EXAMPLE 2

Osteoclast Formation Assay:

Osteoclast formation was determined using the mouse bone marrow-derived osteoblast co-culture system, as described by Takahashi, *et al.*, 1988. In this assay, an osteoblastic cell line (MB1.8), established from neonatal mouse calvaria, were plated in 24-well culture dishes, at 10,000 cells per cm^2 in α-MEM containing 10% fetal bovine serum and 10 nM 1,25(OH)2D3. Balb/C male mice (six weeks old) were sacrificed under CO2, and tibiae and femors were aseptically removed. The bone ends were cut off with scissors and the marrow cavity was flushed with 1 ml α-MEM by using a 27G needle. The bone marrow cells were then filtered through 70 μm nylon mesh. Cells were centrifuged for 7 min. at 300xg and washed once with α-MEM and finally resuspended and aliquoted at 25,000 cells/cm^2 onto the MB1.8 cells in the 24-well culture dishes. Medium with 10 nM 1,25(OH)2D3 was replaced every two days. Potential inhibitors of osteoclast formation were added to the cultures at day 2 and at day 4. After 7 days, the cultures were fixed and stained for Tartrate-resistance acid phosphatase (Trap) activity, essentially as described in Takahashi, *et al.*, 1988. The formation of osteoclasts in this co-culture was quantitated as the number of multinucleated Trap(+) cells (with three or more nuclei) per well of a 24-well tissue culture plate.

Recombinant Expression of functional human integrin $\alpha_v\beta_3$:

cDNAs for human α_v and human β_3 were cloned into pR135 and pCDNAI-neo expression vectors, both of which use the CMV promoter but contain hygromycin or neomycin resistance markers, respectively. Using these selection markers, we established a stable human embryonic kidney 293 cell line that stably expresses high levels of recombinant human $\alpha_v\beta_3$ was established. Surface expression of the

receptor in this 293($\alpha_v\beta_3$) cell line were characterized using northern analysis, surface radioiodination followed by immunoprecipitation. In addition, the number of $\alpha_v\beta_3$ integrin receptors on the cell surface was estimated to be 1 X 10^6 receptor per cell, based on specific binding of $\alpha_v\beta_3$ to radio-iodinated echistatin.

Using the 293($\alpha_v\beta_3$) cell line, two different assays were developed for screening inhibitors of the integrin $\alpha_v\beta_3$: echistatin binding assay (EIB) and vitronectin cell attachment assay (VNADIN), below.

Echistatin Binding assay (EIB):

The membrane fraction of 293($\alpha_v\beta_3$) was solubilized in 100 mM octyl glucoside and the membrane protein extract is used in radio-iodinated echistatin binding. Binding buffer is 1% bovine serum albumin, 50 mM Tris-HCl (pH 7.2), 150 mM NaCl, 1mM $CaCl_2$ and 1mM $MgCl_2$. Membrane extract is incubated with radioiodinated echistatin (50,000 cpm), in the absence (total binding) or in the presence of unlabeled echistatin (specific binding) or in the presence of test compounds. Incubation period is 1 hour at room temperature. Specific echistatin bound proteins are filtered through a membrane using a Skatron Cell Harvester system.

Vitronectin Cell Attachment Assay (VNADIN):

96-well plates are coated with human vitronectin 293($\alpha_v\beta_3$) cells are lifted in trypsin/EDTA and washed in serum-free media. Cells are resuspended in attachment medium (Hank's balance salt containing BSA (1mg/ml) and $CaCl_2$ (2mM). Cells are then allowed to attach to vitronectin-coated wells for 1 hr at 37°C, in the absence (total attachment) or in the presence of tested compounds. Non-adhered cells are then removed by gently washing the wells with phosphate buffered saline.

The number of adhered cells can be quantitated by determining the relative levels of glucosaminidase activity overnight. The enzyme substrate solution is 3.75 mM p-nitrophenyl-N-acetyl-β-D-

glucosaminide in 0.1 M citrate buffer (pH 5.0) and 0.25% Triton X-100. The plates are incubated in the dark, room temperature, overnight. The color reaction is then developed by addition of 50 mM glycine, 5 mM EDTA at pH 10.5. Absorbance at O.D. 405 nm is determined and the number of cells can be quantitated using a standard curve of cells.

Assays using mouse β3:

Essentially the same procedure is followed as described above to create a human embryonic kidney 293 cell line expressing either full-length mouse β3 or mouse β3 trunc. The EIB and/or VNADIN assays are then performed substantially as described, substituting the mouse β3 or mouse β3-trunc expressing cells.

WHAT IS CLAIMED IS:

1. A nucleic acid encoding full-length mouse β3 integrin subunit, said nucleic acid being free from associated mouse nucleic acid.

2. A nucleic acid according to Claim 1 which is DNA.

3. DNA according to Claim 2 which is substantially pure.

4. DNA according to Claim 2 which is cDNA.

5. DNA according to Claim 4 which is shown in Figure 1.

6. A vector comprising any of the nucleic acid of Claims 1-5.

7. A host cell comprising the vector of Claim 6.

8. A host cell according to Claim 7 which is embryonic kidney cells.

9. A method for making full length mouse β3 subunit comprising transforming a host cell with a vector comprising mouse β3 cDNA and harvesting the β3 so produced.

10. Full-length mouse β3 integrin, which is shown in Figure 4, said mouse β3 integrin being free from associated mouse proteins.

11. Substantially pure full length mouse β3 integrin, which is shown in Figure 4.

12. A nucleic acid encoding mouse integrin β3-trunc subunit, said nucleic acid being free from associated mouse nucleic acid.

13. A nucleic acid according to Claim 12 which is DNA.

14. DNA according to Claim 13 which is substantially pure.

15. DNA according to Claim 13 which is cDNA.

16. DNA according to Claim 15 which is shown in Figure 2.

17. A vector comprising any of the nucleic acids of Claims 12-16.

18. A host cell comprising the vector of Claim 17.

19. A method for making mouse β3-trunc comprising transforming a host cell with a vector comprising mouse β3-trunc cDNA and harvesting the β-3 trunc so produced.

20. Mouse β3-trunc integrin, which is shown in Figure 3, said mouse β3-trunc integrin being free from associated mouse proteins.

21. A method to determine the ability a compound to bind to full-length β3 or β3-trunc integrin comprising contacting the compound with either full length β3 or β3-trunc and measuring the resultant binding.

22. A soluble integrin which comprises a binding domain, but which lacks a cytoplasmic domain and a transmembrane domain.

23. A method for identifying a compound which binds to a soluble integrin which possesses a binding domain but which lacks a cytoplasmic domain and a transmembrane domain comprising contacting the compound with the soluble integrin and determining whether binding occurs.

BNSDOCID: <WO 9708316A1>

RECTIFIED SHEET (RULE 91)

```
  1  ATAACAATTT CACACAGGAA ACAGCTATGA CCATGATTAC GCCAAGCTCG
 51  AAATTAACCC TCACTAAAGG GAACAAAAGC TGGAGCTCCA CCGGTGGCGG
101  CCGCTCTAGA ACTAGTGGAT CCCCCGGGCT GCAGGAATTC GCGCCGTCGA
151  CGCGGCGGAC AGGATGCGAG CGCAGTGGCC GGGACAACTC TGGGCCGCTC
201  TGCTGGCGCT GGGGGCGCTG GCGGGCGTTG TTGTTGGAGA GTCCAACATC
251  TGTACCACAC GAGGCGTGAA CTCCTGCCAG CAGTGTCTGG CTGTGAGTCC
301  TGTGTGTGCC TGGTGCTCAG ATGAGACTTT GTCTCAGGGC TCACCCCGAT
351  GTAACCTGAA GGAGAACCTG CTGAAGGACA ATTGTGCTCC AGAGTCTATT
401  GAGTTCCCAG TCAGTGAGGC CCAGATCCTG GAGGCTAGGC CACTCAGCAG
451  CAAGGGCTCT GGAAGCAGCG CCCAGATCAC TCAAGTCAGC CCTCAGAGGA
501  TTGCCCTTCG ACTACGGCCA GATGATTCGA AGATCTTCTC ACTTCAAGTG
551  CGGCAGGTGG AGGATTACCC CGTGGACATC TACTACTTGA TGGACCTGTC
601  TTTCTCCATG AAGGATGATC TGTCCAGCAT CCAGACCCTG GGTACCAAGT
651  TGGCCTCTCA GATGCGCAAG CTTACTAGCA ACCTTCGGAT TGGCTTTGGG
```

FIG. 1A

BNSDOCID: <WO 9708316A1>

RECTIFIED SHEET (RULE 91)

```
 701  GCCTTCGTGG ACAAGCCTGT ATCGCCGTAC ATGTACATCT CCCCACCACA
 751  GGCAATCAAA AACCCCTGTT ACAATATGAA GAATGCCTGC TTGCCCATGT
 801  TTGGCTACAA ACACGTGCTG ACGCTAACCG ACCAGGTGTC CCGCTTCAAT
 851  GAAGAAGTGA AGAAACAGAG CGTGTCCCGT AATCGAGATG CCCCAGAGGG
 901  CGGCTTTGAC GCCATCATGC AGGCTACAGT ATGTGATGAA AAAATTGGCT
 951  GGAGGAATGA CGCATCCCAT TTGCTAGTGT TTACCACGGA TGCCAAGACC
1001  CATATTGCCC TGGATGGAAG ACTGGCAGGC ATTGTCCTGC CCAATGATGG
1051  GCACTGTCAC ATTGGCACCG ACAACCACTA CTCTGCCTCC ACTACCATGG
1101  ACTACCCATC TCTGGGGCTG ATGACTGAGA AACTATCCCA GAAAAACATT
1151  AACTTGATCT TTGCAGTGAC TGAAAATGTC GTCAGCCTTT ACCAGAATTA
1201  TAGTGAGCTC ATTCCTGGGA CCACAGTGGG AGTCCTGTCT GATGACTCAA
1251  GCAACGTCCT CCAGCTGATT GTTGATGCTT ACGGGAAAAT CCGCTCTAAA
1301  GTGGAGCTGG AAGTACGTGA CCTGCCGGAA GAACTGTCAC TGTCCTTCAA
1351  TGCCACCTGC CTCAACAACG AGGTTATCCC GGGCCTCAAG TCTTGTGTGG
```

FIG. 1B

BNSDOCID: <WO 9708316A1>

RECTIFIED SHEET (RULE 91)

```
1401  GCCGCAAGAT TGGAGACACG GTGAGCTTTA GTATCGAGGC CAAGGTGCGT
1451  GGCTGCCCCC AGGAGAAGGA GCAGTCTTTC ACTATCAAGC CTGTGGGCTT
1501  TAAGGACAGC CTCACCGTCC AGGTGACCTT CGACTGTGAC TGTGCCTGCC
1551  AGGCCTTTGC CCAGCCTTCC AGCCCACGCT GCAACAATGG GAACGGGACT
1601  TTTGAGTGTG GGGTGTGCCG CTGTGACCAG GGCTGGCTGG GGTCCATGTG
1651  TGAGTGCTCT GAGGAGGATT ACCGACCCTC TCAGCAGGAA GAGTGCAGCC
1701  CCAAGGAGGG CCAGCCCATC TGCAGCCAGC GGGGAGAGTG CCTCTGTGGC
1751  CAGTGTGTCT GCCATAGCAG CGACTTCGGC AAGATCACTG GCAAGTACTG
1801  TGAGTGCGAT GACTTCTCCT GCGTCCGCTA CAAAGGGGAG ATGTGTTCCG
1851  GCCATGGGCA ATGTAACTGT GGGGACTGCG TGTGTGACTC GGACTGGACT
1901  GGCTACTACT GCAACTGTAC TACACGCACT GACACCTGCA TGTCCACCAA
1951  TGGGCTGCTG TGCAGCGGCC GGGGCAACTG CGAGTGCGGC AGCTGTGTGT
2001  GCGTCCAGCC AGGCTCCTAT GGAGACACCT GTGAGAAGTG CCCCACCTGC
2051  CCAGATGCCT GCTCCTTTAA GAAGGAGTGT GTGGAGTGTA AGAAGTTCAA
```

FIG. 1C

BNSDOCID: <WO 9708316A1>

RECTIFIED SHEET (RULE 91)

```
2101  CCGGGGAACG CTCCATGAAG AAAACACCTG CAGCCGCTAC TGCCGGGATG
2151  ACATCGAGCA GGTGAAAGAG CTGACGGATA CTGGCAAAAA CGCCGTGAAT
2201  TGTACCTACA AGAACGAGGA TGACTGTGTC GTCAGATTCC AGTACTACGA
2251  AGACACCAGT GGGAGGGCAG TCCTCTATGT GGTGGAAGAG CCTGAGTGTC
2301  CCAAGGGTCC TGATATCCTG GTGGTACTGC TGTCAGTGAT GGGGGCCATC
2351  CTGCTCATTG GCCTTGCTAC TCTGCTCATC TGGAAGCTAC TCATCACCAT
2401  CCATGACCGG AAGGAATTTG CTAAATTTGA GGAAGAACGA GCCAGAGCTA
2451  AGTGGGACAC AGCAAACAAC CCGCTGTATA AAGAGGCCAC CTCCACCTTC
2501  ACCAATATCA CGTACCGAGG AACTTAATGA
```

FIG. 1D

BNSDOCID: <WO 9708316A1>

RECTIFIED SHEET (RULE 91)

```
   1  ATAACAATTT CACACAGGAA ACAGCTATGA CCATGATTAC GCCAAGCTCG
  51  AAATTAACCC TCACTAAAGG GAACAAAAGC TGGAGCTCCA CCGGTGGCGG
 101  CCGCTCTAGA ACTAGTGGAT CCCCCGGGCT GCAGGAATTC GCGCCGTCGA
 151  CGCGGCGGAC AGGATGCGAG CGCAGTGGCC GGGACAACTC TGGGCCGCTC
 201  TGCTGGCGCT GGGGGCGCTG GCGGGCGTTG TTGTTGGAGA GTCCAACATC
 251  TGTACCACAC GAGGCGTGAA CTCCTGCCAG CAGTGTCTGG CTGTGAGTCC
 301  TGTGTGTGCC TGGTGCTCAG ATGAGACTTT GTCTCAGGGC TCACCCCGAT
 351  GTAACCTGAA GGAGAACCTG CTGAAGGACA ATTGTGCTCC AGAGTCTATT
 401  GAGTTCCCAG TCAGTGAGGC CCAGATCCTG GAGGCTAGGC CACTCAGCAG
 451  CAAGGGCTCT GGAAGCAGCG CCCAGATCAC TCAAGTCAGC CCTCAGAGGA
 501  TTGCCCTTCG ACTACGGCCA GATGATTCGA AGATCTTCTC ACTTCAAGTG
 551  CGGCAGGTGG AGGATTACCC CGTGGACATC TACTACTTGA TGGACCTGTC
 601  TTTCTCCATG AAGGATGATC TGTCCAGCAT CCAGACCCTG GGTACCAAGT
 651  TGGCCTCTCA GATGCGCAAG CTTACTAGCA ACCTTCGGAT TGGCTTTGGG
```

FIG. 2A

BNSDOCID: <WO 9708316A1>

RECTIFIED SHEET (RULE 91)

```
 701  GCCTTCGTGG ACAAGCCTGT ATCGCCGTAC ATGTACATCT CCCCACCACA
 751  GGCAATCAAA AACCCCTGTT ACAATATGAA GAATGCCTGC TTGCCCATGT
 801  TTGGCTACAA ACACGTGCTG ACGCTAACCG ACCAGGTGTC CCGCTTCAAT
 851  GAAGAAGTGA AGAAACAGAG CGTGTCCCGT AATCGAGATG CCCCAGAGGG
 901  CGGCTTTGAC GCCATCATGC AGGCTACAGT ATGTGATGAA AAAATTGGCT
 951  GGAGGAATGA CGCATCCCAT TTGCTAGTGT TTACCACGGA TGCCAAGACC
1001  CATATTGCCC TGGATGGAAG ACTGGCAGGC ATTGTCCTGC CCAATGATGG
1051  GCACTGTCAC ATTGGCACCG ACAACCACTA CTCTGCCTCC ACTACCATGG
1101  ACTACCCATC TCTGGGGCTG ATGACTGAGA AACTATCCCA GAAAAACATT
1151  AACTTGATCT TTGCAGTGAC TGAAAATGTC GTCAGCCTTT ACCAGAATTA
1201  TAGTGAGCTC ATTCCTGGGA CCACAGTGGG AGTCCTGTCT GATGACTCAA
1251  GCAACGTCCT CCAGCTGATT GTTGATGCTT ACGGGAAAAT CCGCTCTAAA
1301  GTGGAGCTGG AAGTACGTGA CCTGCCGGAA GAACTGTCAC TGTCCTTCAA
1351  TGCCACCTGC CTCAACAACG AGGTTATCCC GGGCCTCAAG TCTTGTGTGG
```

FIG. 2B

RECTIFIED SHEET (RULE 91)

RNSDOCID: <WO 9708316A1>

```
1401  GCCGCAAGAT TGGAGACACG GTGAGCTTTA GTATCGAGGC CAAGGTGCGT
1451  GGCTGCCCCC AGGAGAAGGA GCAGTCTTTC ACTATCAAGC CTGTGGGCTT
1501  TAAGGACAGC CTCACCGTCC AGGTGACCTT CGACTGTGAC TGTGCCTGCC
1551  AGGCCTTTGC CCAGCCTTCC AGCCCACGCT GCAACAATGG GAACGGGACT
1601  TTTGAGTGTG GGGTGTGCCG CTGTGACCAG GGCTGGCTGG GGTCCATGTG
1651  TGAGTGCTCT GAGGAGGATT ACCGACCCTC TCAGCAGGAA GAGTGCAGCC
1701  CCAAGGAGGG CCAGCCCATC TGCAGCCAGC GGGGAGAGTG CCTCTGTGGC
1751  CAGTGTGTCT GCCATAGCAG CGACTTCGGC AAGATCACTG GCAAGTACTG
1801  TGAGTGCGAT GACTTCTCCT GCGTCCGCTA CAAAGGGGAG ATGTGTTCCG
1851  GCCATGGGCA ATGTAACTGT GGGGACTGCG TGTGTGACTC GGACTGGACT
1901  GGCTACTACT GCAACTGTAC TACACGCACT GACACCTGCA TGTCCACCAA
1951  TGGGCTGCTG TGCAGCGGCC GGGGCAACTG CGAGTGCGGC AGCTGTGTGT
2001  GCGTCCAGCC AGGCTCCTAT GGAGACACCT GTGAGAAGTG CCCCACCTGC
2051  CCAGATGCCT GCTCCTTTAA GAAGGAGTGT GTGGAGTGTA AGAAGTTCAA
```

FIG. 2C

BNSDOCID: <WO 9708316A1>

RECTIFIED SHEET (RULE 91)

```
2101  CCGGGGAACG CTCCATGAAG AAAACACCTG CAGCCGCTAC TGCCGGGATG
2151  ACATCGAGCA GGTGAAAGAG CTGACGGATA CTGGCAAAAA CGCCCGCGGC
2201  CGCGTCGACT GGAGACTCAC GGAGCATGAC ATACTCACCT GTCACCTATT
2251  TAGAAGACTG AGGCAGGAAG ATAAGTTTCT GGACAGCCTA GTCTGCATAA
2301  AGACCACCCT GTCTCAAAAA GCATAAAAGG GGCGTGGTGA ATGCCTGCTT
2351  AGCATATAGC CCTTGGTTGC AGGTAGTGCA GTACATAGGT GAAATCTGCC
2401  GCTACCTGCT GAGGCAGCCG GTTCGCGACG TGGAGCAGCG ACACCGCGTG
2451  CGCCTGGCCG CGGGTAATGG GCTGCGGCCA GCCATCTGGG AGGAGTTCAC
2501  GCAGCGCTTC GGTGTGCCAC AGATCGGCGA GTTCTACGGC GCTACCGAGT
2551  GCAACTGAGC ATTGCCAACA TGGACGGCAA GGTTCGCAGC TGTGGGGTGC
2601  AGGCGGGCGC TGTCGGTTTC CTACGACACA AGAGCCTTCA GGCCGCCCTC
2651  ACCGCCGCTG TATTCACCCT AGGTCGGCTC CTGCGGCTTC AACAGCCGTA
2701  TCCTCACGCA TGTGTACCCC ATCCGTCTGG TCAAGGTCAA TGAGGACACG
2751  ATGGAGCCAC TGCGGGACTC CGAGGGCCTC TGCATCCCGT GCCAGCCCGG
```

FIG. 2D

BNSDOCID: <WO 9708316A1>

RECTIFIED SHEET (RULE 91)

2801 TGAGTGTGGC CCTTGCCTGG TGCCTCGGGG AGCTAGAGTC CCCACGGCCC

2851 CCACACCCAC TCAGCTTGAG TGTCAACCTC CTTCCAGGGG AACCCGGCCT

2901 TTCGTGGGCC AGATCAACCA GCAGGACCCT CTGCGGCGTT TCGATGGTTA

2951 TGTTAGTGAC AGTGCCACCA ACAAGAAGAT TGCCCACAGC GTTTTCCGAA

3001 AGGCGATACG gCCTACCTCT CAGGTGCGGA CGCTCGTGGT CGTGGCTGGG

3051 CTGGCTGTCA GACTGCAAAG CCCGGTCCCA TCTGCCCCTC TTCCCTGCAG

3101 GTGACGTGCT AGTGATGGAC GAGCTGGGCT ACATGTATTT CCGTGACCGC

3151 AGCGGGGACA CCTTCCGCTG GCGCGGGAGA ACGTGTCCAA CCACGGAGGT

3201 GAAGCCGGTG CTGAGCCGCC TACTGGGCCA GACGGACGTG GCTGTGTATG

3251 GGGTGGCTGT GCAGGCAAGC TGGGGACACA GGGTGGTTGT GGTGTGCAGG

3301 AGCCCCATGG AGTCCATCCA GAAGGGACCT GCAGGTACAG TACCCGTGGG

3351 CCATGCACAA GGTGGAGAAC TGTGTTGCTG CTGACTGGGT GGGCACTGGG

3401 TTGGGAATCC ATCCACATTC CTAATATTGA ACTTCAGTCT GGGGGACCCC

3451 TTCTCAGGAT CAGAAGGCTG AAAACAGGTC GACGCCGCCC GGAATTCGAT

3501 ATCAAGCTTA TCGATCC

FIG. 2E

BNSDOCID: <WO 9708316A1>

RECTIFIED SHEET (RULE 91)

```
  1  *QFHTGNSYD HDYAKLEINP H*REQKLELH RWRPL*N*WI PRAAGIRAVD
 51  AADRMRAQWP GQLWAALLAL GALAGVVVGE SNICTTRGVN SCQQCLAVSP
101  VCAWCSDETL SQGSPRCNLK ENLLKDNCAP ESIEFPVSEA QILEARPLSS
151  KGSGSSAQIT QVSPQRIALR LRPDDSKIFS LQVRQVEDYP VDIYYLMDLS
201  FSMKDDLSSI QTLGTKLASQ MRKLTSNLRI GFGAFVDKPV SPYMYISPPQ
251  AIKNPCYNMK NACLPMFGYK HVLTLTDQVS RFNEEVKKQS VSRNRDAPEG
301  GFDAIMQATV CDEKIGWRND ASHLLVFTTD AKTHIALDGR LAGIVLPNDG
351  HCHIGTDNHY SASTTMDYPS LGLMTEKLSQ KNINLIFAVT ENVVSLYQNY
401  SELIPGTTVG VLSDDSSNVL QLIVDAYGKI RSKVELEVRD LPEELSLSFN
451  ATCLNNEVIP GLKSCVGRKI GDTVSFSIEA KVRGCPQEKE QSFTIKPVGF
501  KDSLTVQVTF DCDCACQAFA QPSSPRCNNG NGTFECGVCR CDQGWLGSMC
551  ECSEEDYRPS QQEECSPKEG QPICSQRGEC LCGQCVCHSS DFGKITGKYC
601  ECDDFSCVRY KGEMCSGHGQ CNCGDCVCDS DWTGYYCNCT TRTDTCMSTN
651  GLLCSGRGNC ECGSCVCVQP GSYGDTCEKC PTCPDACSFK KECVECKKFN
```

FIG. 3A

BNSDOCID: <WO 9708316A1>

RECTIFIED SHEET (RULE 91)

```
 701  RGTLHEENTC SRYCRDDIEQ VKELTDTGKN ARGRVDWRLT EHDILTCHLF
 751  RRLRQEDKFL DSLVCIKTTL SQKA*KGRGE CLLSI*PLVA GSAVHR*NLP
 801  LPAEAAGSRR GAATPRAPGR G*WAAASHLG GVHAALRCAT DRRVLRRYRV
 851  QLSIANMDGK VRSCGVQAGA VGFLRHKSLQ AALTAAVFTL GRLLRLQQPY
 901  PHACVPHPSG QGQ*GHDGAT AGLRGPLHPV PAR*VWPLPG ASGS*SPHGP
 951  HTHSA*VSTS FQGNPAFRGP DQPAGPSAAF RWLC**QCHQ QEDCPQRFPK
1001  GDTAYLSGAD ARGRGWAGCQ TAKPGPICPS SLQVTC**WT SWATCISVTA
1051  AGTPSAGAGE RVQPRR*SRC *AAYWARRTW LCMGWLCRQA GDTGWLWCAG
1101  APWSPSRRDL QVQYPWAMHK VENCVAADWV GTGLGIHPHS *Y*TSVWGTP
1151  SQDQKAENRS TPPGIRYQAY RS
```

FIG. 3B

BNSDOCID: <WO 9708316A1>

RECTIFIED SHEET (RULE 91)

```
  1  *QFHTGNSYD HDYAKLEINP H*REQKLELH RWRPL*N*WI PRAAGIRAVD
 51  AADRMRAQWP GQLWAALLAL GALAGVVVGE SNICTTRGVN SCQQCLAVSP
101  VCAWCSDETL SQGSPRCNLK ENLLKDNCAP ESIEFPVSEA QILEARPLSS
151  KGSGSSAQIT QVSPQRIALR LRPDDSKIFS LQVRQVEDYP VDIYYLMDLS
201  FSMKDDLSSI QTLGTKLASQ MRKLTSNLRI GFGAFVDKPV SPYMYISPPQ
251  AIKNPCYNMK NACLPMFGYK HVLTLTDQVS RFNEEVKKQS VSRNRDAPEG
301  GFDAIMQATV CDEKIGWRND ASHLLVFTTD AKTHIALDGR LAGIVLPNDG
351  HCHIGTDNHY SASTTMDYPS LGLMTEKLSQ KNINLIFAVT ENVVSLYQNY
401  SELIPGTTVG VLSDDSSNVL QLIVDAYGKI RSKVELEVRD LPEELSLSFN
451  ATCLNNEVIP GLKSCVGRKI GDTVSFSIEA KVRGCPQEKE QSFTIKPVGF
501  KDSLTVQVTF DCDCACQAFA QPSSPRCNNG NGTFECGVCR CDQGWLGSMC
551  ECSEEDYRPS QQEECSPKEG QPICSQRGEC LCGQCVCHSS DFGKITGKYC
601  ECDDFSCVRY KGEMCSGHGQ CNCGDCVCDS DWTGYYCNCT TRTDTCMSTN
651  GLLCSGRGNC ECGSCVCVQP GSYGDTCEKC PTCPDACSFK KECVECKKFN
```

FIG. 4A

```
701  RGTLHEENTC SRYCRDDIEQ VKELTDTGKN AVNCTYKNED DCVVRFQYYE

751  DTSGRAVLYV VEEPECPKGP DILVVLLSVM GAILLIGLAT LLIWKLLITI

801  HDRKEFAKFE EERARAKWDT ANNPLYKEAT STFTNITYRG T**
```

FIG. 4B

BNSDOCID: <WO 9708316A1>

```
       55
MRAQWPGQLWAALLALGALAGVVVGESNICTTRGVNSCQQCLAVSPVCAW 104

||||||||||||||||||||||||||||||||||||||||||||||||||
       55
MRAQWPGQLWAALLALGALAGVVVGESNICTTRGVNSCQQCLAVSPVCAW 104

     105
CSDETLSQGSPRCNLKENLLKDNCAPESIEFPVSEAQILEARPLSSKGSG 154

||||||||||||||||||||||||||||||||||||||||||||||||||
     105
CSDETLSQGSPRCNLKENLLKDNCAPESIEFPVSEAQILEARPLSSKGSG 154

     155
SSAQITQVSPQRIALRLRPDDSKIFSLQVRQVEDYPVDIYYLMDLSFSMK 204

||||||||||||||||||||||||||||||||||||||||||||||||||
     155
SSAQITQVSPQRIALRLRPDDSKIFSLQVRQVEDYPVDIYYLMDLSFSMK 204

     205
DDLSSIQTLGTKLASQMRKLTSNLRIGFGAFVDKPVSPYMYISPPQAIKN 254

||||||||||||||||||||||||||||||||||||||||||||||||||
     205
DDLSSIQTLGTKLASQMRKLTSNLRIGFGAFVDKPVSPYMYISPPQAIKN 254

     255
PCYNMKNACLPMFGYKHVLTLTDQVSRFNEEVKKQSVSRNRDAPEGGFDA 304

||||||||||||||||||||||||||||||||||||||||||||||||||
     255
PCYNMKNACLPMFGYKHVLTLTDQVSRFNEEVKKQSVSRNRDAPEGGFDA 304
```

FIG. 5A

RECTIFIED SHEET (RULE 91)

BNSDOCID: <WO 9708316A1>

```
      305
IMQATVCDEKIGWRNDASHLLVFTTDAKTHIALDGRLAGIVLPNDGHCHI 354
||||||||||||||||||||||||||||||||||||||||||||||||||
      305
IMQATVCDEKIGWRNDASHLLVFTTDAKTHIALDGRLAGIVLPNDGHCHI 354

      355
GTDNHYSASTTMDYPSLGLMTEKLSQKNINLIFAVTENVVSLYQNYSELI 404
||||||||||||||||||||||||||||||||||||||||||||||||||
      355
GTDNHYSASTTMDYPSLGLMTEKLSQKNINLIFAVTENVVSLYQNYSELI 404

      405
PGTTVGVLSDDSSNVLQLIVDAYGKIRSKVELEVRDLPEELSLSFNATCL 454
||||||||||||||||||||||||||||||||||||||||||||||||||
      405
PGTTVGVLSDDSSNVLQLIVDAYGKIRSKVELEVRDLPEELSLSFNATCL 454

      455
NNEVIPGLKSCVGRKIGDTVSFSIEAKVRGCPQEKEQSFTIKPVGFKDSL 504
||||||||||||||||||||||||||||||||||||||||||||||||||
      455
NNEVIPGLKSCVGRKIGDTVSFSIEAKVRGCPQEKEQSFTIKPVGFKDSL 504

      505
TVQVTFDCDCACQAFAQPSSPRCNNGNGTFECGVCRCDQGWLGSMCECSE 554
||||||||||||||||||||||||||||||||||||||||||||||||||
      505
TVQVTFDCDCACQAFAQPSSPRCNNGNGTFECGVCRCDQGWLGSMCECSE 554
```

FIG. 5B

RECTIFIED SHEET (RULE 91)

BNSDOCID: <WO 9708316A1>

```
     555
EDYRPSQQEECSPKEGQPICSQRGECLCGQCVCHSSDFGKITGKYCECDD 604

||||||||||||||||||||||||||||||||||||||||||||||||||||
     555
EDYRPSQQEECSPKEGQPICSQRGECLCGQCVCHSSDFGKITGKYCECDD 604

     605
FSCVRYKGEMCSGHGQCNCGDCVCDSDWTGYYCNCTTRTDTCMSTNGLLC 654

||||||||||||||||||||||||||||||||||||||||||||||||||||
     605
FSCVRYKGEMCSGHGQCNCGDCVCDSDWTGYYCNCTTRTDTCMSTNGLLC 654

     655
SGRGNCECGSCVCVQPGSYGDTCEKCPTCPDACSFKKECVECKKFNRGTL 704

||||||||||||||||||||||||||||||||||||||||||||||||||||
     655
SGRGNCECGSCVCVQPGSYGDTCEKCPTCPDACSFKKECVECKKFNRGTL 704

     705
HEENTCSRYCRDDIEQVKELTDTGKNAVNCTYKNEDDCVVRFQYYEDTSG 754
         ||||||||||||||||||||||||||          . | :.. |..
     705
HEENTCSRYCRDDIEQVKELTDTGKNA.........RGRVDWRLTEHDIL 745

     755 RAVLYVVEEPECPKGPDILVVLLSVMGA 782
          . |:    .| .|  | ||.: ..:.
     746 TCHLFRRLRQE.DKFLDSLVCIKTTLSQ 772
```

FIG. 5C

BNSDOCID: <WO 9708316A1>



FIG.6B

FIG.6A

BNSDOCID: <WO 9708316A1>



FIG.7

BNSDOCID: <WO 9708316A1>


β3-Trunc
Heart
Brain
Spleen
Lung
Liver
Skeletal Muscle
Kidney
Testes
9.5 kb
7.5 kb
4.4 kb
2.4 kb
1.35 kb
β3
β-Actin

FIG.8B

FIG.8A



FIG. 9

BNSDOCID: <WO 9708316A1>

INTERNATIO[illegible] SEARCH REPORT

[illegible]ional application No.
[illegible]T/US96/13805

A. CLASSIFICATION OF SUBJECT MATTER

IPC(6) :C12N 15/12, 15/63, 15/70, 15/79; C07K 14/705
US CL :536/23.5, 530/350, 435/69.1, 320.1, 240.2, 252.3

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 536/23.5, 530/350, 435/69.1, 320.1, 240.2, 252.3

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

APS, Medline, Hcaplus
search terms: beta 3, integrin#, murine, mouse

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	CIEUTAT, A.-M. et al. A Comparative Analysis of cDNA-Derived Sequences for Rat and Mouse β_3 Integrins (GPIIIa) with their Human Counterpart. Biochem. Biophys. Res. Comm. 15 June 1993. Vol. 193, No. 2, pages 771-778, especially pages 774-775.	1-20
Y	DJAFFAR, I. et al. A New Alternative Transcript Encodes a 60 kDa Truncated Form of Integrin β_3. Biochem. J. 15 May 1994. Vol. 300, Pt. 1, pages 69-74, especially page 72.	12-20
Y	FITZGERALD, L.A. et al. Protein Sequence of Endothelial Glycoprotein IIIa Derived from a cDNA Clone. J. Biol. Chem. 25 March 1987. Vol. 262, No. 9, pages 3936-3939, especially page 3937.	1-11

[X] Further documents are listed in the continuation of Box C. [ ] See patent family annex.

*	Special categories of cited documents:	"T"	later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
"A"	document defining the general state of the art which is not considered to be of particular relevance	"X"	document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
"E"	earlier document published on or after the international filing date	"Y"	document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
"L"	document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	"&"	document member of the same patent family
"O"	document referring to an oral disclosure, use, exhibition or other means		
"P"	document published prior to the international filing date but later than the priority date claimed		

Date of the actual completion of the international search 27 OCTOBER 1996	Date of mailing of the international search report 07 NOV 1996
Name and mailing address of the ISA/US Commissioner of Patents and Trademarks Box PCT Washington, D.C. 20231 Facsimile No. (703) 305-3230	Authorized officer KAREN E. BROWN Telephone No. (703) 308-0196

Form PCT/ISA/210 (second sheet)(July 1992)*

BNSDOCID: <WO 9708316A1>

C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	VAN KUPPEVELT, T.H.M.S.M. et al. An Alternative Cytoplasmic Domain of the Integrin β_3 Subunit. Proc. Natl. Acad. Sci. USA. July 1989. Vol. 86, No. 14, pages 5415-5418, especially page 5416.	12-20
Y	US 5,391,704 A (McMILLAN ET AL.) 21 February 1995, column 19, lines 26-54.	6-11, 17-20

BNSDOCID: <WO 9708316A1>